These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1552 related items for PubMed ID: 25439852

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A.
    Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.
    Dold M, Aigner M, Lanzenberger R, Kasper S.
    Int J Neuropsychopharmacol; 2013 Apr; 16(3):557-74. PubMed ID: 22932229
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study.
    Bogan AM, Koran LM, Chuong HW, Vapnik T, Bystritsky A.
    J Clin Psychiatry; 2005 Jan; 66(1):73-9. PubMed ID: 15669891
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
    Matsunaga H, Nagata T, Hayashida K, Ohya K, Kiriike N, Stein DJ.
    J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
    Maher AR, Theodore G.
    J Manag Care Pharm; 2012 Jun; 18(5 Suppl B):S1-20. PubMed ID: 22784311
    [Abstract] [Full Text] [Related]

  • 16. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J, Marcus SM, Williams MT, Weaver J, Vermes D, Van Meter PE, Rodriguez CI, Powers M, Pinto A, Imms P, Hahn CG, Campeas R.
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [Abstract] [Full Text] [Related]

  • 17. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
    Dold M, Aigner M, Lanzenberger R, Kasper S.
    Int J Neuropsychopharmacol; 2015 May 04; 18(9):. PubMed ID: 25939614
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis.
    Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J.
    BMC Psychiatry; 2014 Nov 29; 14():317. PubMed ID: 25432131
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 78.